Gold Track worked with Eligo Bioscience on developing a comprehensive business story highlighting their exciting technology, exceptional management team, and unmet clinical needs. Congratulations to Eligo! In November 2023, Eligo Biosciences secured $30 million in Series B funding. These funds are earmarked for obtaining early human data for their lead candidate, which is focused on addressing moderate to severe acne vulgaris, through a Phase 1b/2a clinical trial.